Galapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in atopic dermatitis (also known as eczema).
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh